The Lancet regional health. Africa
Treatment outcomes and post-treatment mortality among people with multidrug/rifampicin-resistant tuberculosis in Sierra Leone: a national cohort study
By Greenwood F, Kamara RF, Harding R and 4 others.
Abstract
Background
Evidence on biosocial factors driving adverse outcomes in multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB) can inform design of person-centred interventions. We evaluated treatment outcomes, post-treatment mortality, and their associated risk factors among people with multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB) in Sierra Leone.
Methods
We did a national cohort study of people with MDR/RR-TB in Lakka Hospital, Freetown, 2017-2022. Treatment was with WHO-recommended short (9-11 month) or long (18-24 month) regimens, with adverse treatment outcome (death or loss to follow-up before or during treatment, or treatment failure) following WHO definitions. Participants with treatment success had 12-months follow-up to ascertain post-treatment mortality. We used directed acyclical graph-informed logistic regression to investigate biosocial factors associated with adverse treatment outcome and post-treatment mortality.